Last reviewed 2026-04-19 · How we verify

Arteriosclerotic vascular disease

Approved treatments

• Lescol · Novartis
  Fluvastatin sodium inhibits HMG-CoA reductase, reducing cholesterol biosynthesis and increasing LDL receptor activity, lowering plasma cholesterol.
• Lipitor · Pfizer Inc.
  Selective competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis.
• Zocor · Merck & Co.
• Crestor · AstraZeneca
  Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme converting HMG-CoA to mevalonate, a cholesterol precursor.
• Lipitor · Pfizer
  Lipitor is a selective, competitive inhibitor of HMG-CoA reductase, a key enzyme in cholesterol synthesis.
• Mevacor · Merck & Co.
  Mevacor works by inhibiting the enzyme HMG-CoA reductase, which plays a key role in cholesterol production in the liver.

Clinical guidelines

• FDA label — 1L
  To reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults without established coronary heart disease who are at increased risk of CV disease based on age, high-sensitivity C-reactive protein (hsCRP) ≥2 mg/L, and at least one additional CV risk factor.
• FDA label — 1L
  To reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults without established coronary heart disease who are at increased risk of CV disease based on age, high-sensitivity C-reactive protein (hsCRP) ≥2 mg/L, and at least one additional CV risk factor.
• FDA label — 1L
  To reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults without established coronary heart disease who are at increased risk of CV disease based on age, high-sensitivity C-reactive protein (hsCRP) ≥2 mg/L, and at least one additional CV risk factor.
• FDA label — 1L
  To reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults without established coronary heart disease who are at increased risk of CV disease based on age, high-sensitivity C-reactive protein (hsCRP) ≥2 mg/L, and at least one additional CV risk factor.

Competitive intelligence

For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:

• Arteriosclerotic vascular disease patent landscape — cliff calendar, originator estates, attackable patents
• Arteriosclerotic vascular disease treatment landscape brief
• Arteriosclerotic vascular disease treatment updates RSS

Frequently asked questions about Arteriosclerotic vascular disease

Related

• Treatment landscape: Arteriosclerotic vascular disease patent cliff · Arteriosclerotic vascular disease CI report
• Treatment: Lescol · Novartis
• Treatment: Lipitor · Pfizer Inc.
• Treatment: Zocor · Merck & Co.
• Treatment: Crestor · AstraZeneca
• Treatment: Lipitor · Pfizer
• All diseases: Browse the disease index · Disease landscape hub

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing